Headlines

Danaher Corporation (DHR) Q4 2025 (USD): Adj EPS 2.23 (exp. 2.16), Revenue 6.84bln (exp. 6.80bln), Current FY EPS 7.80 (exp. 7.73), Next FY EPS 8.50 (exp. 8.42)

Newsquawk Staff ·

  • Biotechnology Revenue 2.03bln (exp. 2.03bln)
  • Life Sciences 2.09bln (exp. 2.07bln) 

What it means

Danaher Corporation exceeded expectations with its Q4 2025 results, posting higher-than-expected adjusted EPS and revenue. This performance not only beats estimates for the current fiscal year but also for FY 2026, suggesting strong operational momentum and potential bullish sentiment in the life sciences sector. The results may positively influence Danaher's stock and set a favorable tone for its peers in the biotechnology and life sciences space.

Related headlines